Skip to main content

Table 1 Clinical and demographic features of the 10 patients with early diffuse SSc

From: Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features

Sex/age (years) Year of SSc onset/disease duration at skin-BM biopsy (years) MRSS/score at skin biopsy Autoantibodies Lung involvment HRCT/PFT Heart involvement/scleroderma renal crisis Raynaud’s phenomenon/digital ulcers
F/46 2010/2 12/2 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/21 2009/3 13/1 ANA/Scl-70 Normal/Normal Normal/No Yes/Yes
F/31 2011/1 13/2 ANA/Scl7-0 Normal/Normal Normal/No Yes/Yes
F/36 2010/2 11/2 ANA/Scl-70 Normal/Normal PAH/No Yes/Yes
M/20 2010/2 11/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/41 2010/2 15/2 ANA/Scl-70 Normal/Normal Normal/No No/No
F/30 2010/2 10/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/21 2010/2 09/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/31 2009/3 14/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/42 2009/3 16/2 ANA/Scl-70 Fibrosis/Normal Normal/No Yes/No
  1. M, male; F, female; MRSS, modified Rodnan skin thickness score (maximum possible score 51); HRCT, high-resolution computed tomography; PFT, pulmonary function test; ANA, antinuclear antibodies; ACA, anti-centromere antibodies; scl-70, anti-topoisomerase antibodies; PAH, pulmonary arterial hypertension.